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Background: Over the past decade, several changes occurred in diagnostics, treatment and under-
standing of pathogenesis of gastrointestinal stromal tumours (GIST). However, their coexistence with
other malignancies of different histogenetic origin remains a challenging issue.
Methods: Patients diagnosed with GIST in a 10-years period were identiﬁed retrospectively and clinical
history and ﬁndings thoroughly explored for the presence of associated other malignancies. Follow up
data were obtained and analysed for prognostic impact of the concurrent malignancy and/or GIST.
Results: Thirty seven (27 males, 10 females) of 86 GIST-patients (43%) had another malignancy. Mean age
was 70 years. Associated malignancies were gastrointestinal (n ¼ 29; 69%), renal-/urological (n ¼ 5; 12%),
haematological (n ¼ 4; 9.5%), cutaneous (n ¼ 3; 7%) and thyroid (n ¼ 1; 2.5%) in origin. Majority of GISTs
occurred in stomach (65%) and small intestine (30.6%) and most (78%) were asymptomatic incidental
ﬁndings during diagnostic or therapeutic procedures for associated malignancies. GIST size ranged from
0.1 cm to 9 cm (mean, 2.2 cm) and all of them had a low (<5/50HPFs) or no mitotic activity. Thirty-one
tumours (84%) were of no/very low/low risk and 6 were of intermediate risk. During follow-up (range 3
e160 months, mean; 60 months), one patient suffered from distant metastases of GIST. Seven patients
(19%) died of associated malignancies and three patients (8%) of other non-tumour-associated cause, but
none died of GIST.
Conclusion: Coexistence of GIST with other malignancies is higher than previously reported and should
draw attention of clinicians towards these incidental ﬁndings. Prognosis in these patients is usually
determined by other malignancy and not signiﬁcantly inﬂuenced by GIST. Therefore treatment algo-
rithms should be focused on prognostically relevant malignancy.
 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Gastrointestinal stromal tumours (GIST) represent the most
common mesenchymal tumours of the digestive tract. GIST are
thought to derive from or differentiate similar to the gastrointestinal
pacemaker cells, the interstitial cells of Cajal or their multipotential
mesenchymal precursor cells [1,2]. GIST may be composed either of
spindle, epithelioid, or pleomorphic cells or a variable combination
thereof [3]. Most GISTs are initiated by oncogenic mutations
involving the receptor tyrosine kinase proto-oncogenes c-kit and
the platelet-derived growth factor receptor alpha (PDGFRA) gene
[4,5]. Their clinical symptoms depend on the tumour size and theniversity of Erlangen, Kran-
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by Elsevier Ltd. All rights reservedlocalisation. In some cases GIST represent incidental ﬁndings either
during surgery, at autopsy or during other diagnostic procedures for
unrelated diseases. Metastases arise predominantly in the liver or in
the peritoneum, but rarely in lymph nodes, bones, lungs and other
rare sites [6]. A prognostic classiﬁcation of GIST into four [7] or ﬁve
[8] risk categories is based on tumour size, mitotic activity and/or
site. Their therapeutic options include surgery and treatment with
imatinib mesylate (Glivec, Novartis, Basel, Switzerland), a competi-
tive inhibitor of tyrosine kinases (BCR-ABL, ARG, KIT, PDGFRa and
PDGFRb) [9,10]. A majority of patients respond to imatinib mesylate
or achieve durable tumour growth stabilisation allowing a R0-
resection, but some initially responsive patients experience
tumour progress because of secondary drug resistance [11]. Unusual
phenotypic changes may occur in GIST after neoadjuvant imatinib
treatment [12].
The management of GIST has dramatically altered over the last
years as a consequence of several achievements on the part of.
Fig. 1. a. Typical appearance of a GIST of very low risk localisated in the stomach
during surgery for adenocarcinoma of eosophagus. b. Typical extramural appearance of
an incidentally identiﬁed GIST of the small intestine during surgery for ductal
adenocarcinoma of pancreas.
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Although several studies have documented the relatively common
synchronous or asynchronous coexistence of GIST with other
unrelated malignant neoplasms, still little is known on the sig-
niﬁcance and prognostic impact of their association with other
malignancies of different anatomic localisation and histogenetic
derivation. With increased awareness of the disease, nowadays
the coexistence of GIST with other malignancies is more often
detected than initially considered. Most of these cases have been
documented as single case reports but several case series and
reviews also exist on this topic [13]. This phenomenon remains
still a special and challenging situation during multimodal
therapy.
We report our experience from a single institutionwith patients
diagnosed with GIST and a second neoplasm occurring in a syn-
chronous or asynchronous setting.
2. Material and methods
2.1. Patients, malignancies and follow up
At our institution, 86 patients with GIST were treated within a period of 10
years (between January 2000 and December 2009). The analysis encompassed
those patients, who were identiﬁed with another type of malignant neoplasia. The
time point of GIST diagnosis with regard to the diagnosis of the other malignancies
was deﬁned as either synchronous (during staging or surgical therapy of the
diagnosed cancer) or non-synchronous (before the diagnosis of the other-type of
cancer or after its treatment). GIST diagnosis was veriﬁed according to current
diagnosis criteria [8]. Immunohistochemical staining was performed with CD117,
CD34, desmin, and S100 as previously. Mitoses were counted in 50 high-power
ﬁelds (HPFs). One HPF corresponded to an area of 0.238.mm2. The risk category
was deﬁned by assessing the tumour size and mitotic count following the
consensus guidelines of the National Institutes of Health-(NIH-NCI) workshop and
the Miettinen’s criteria [7,8].
Associated malignant neoplasms were classiﬁed according to current World
Health Organisation (WHO) classiﬁcation of malignant neoplasm, the UICC
criteria and TNM classiﬁcation [14,15]. Neuroﬁbromatosis type 1 (NF-1) and
Carney triad-associated tumours or familial GIST were excluded from this study.
Clinical and histopathological records were reviewed and data from cooperating
hospitals and general practitioners were included. Patient, age, sex, tumour
localization, morphological variant (spindle-cell, epithelioid, mixed), malignant
potential (risk classiﬁcation) and selected immunohistochemical parameters
were assessed. The mean follow up of patients was 60 months (range: 3e160
months).
3. Results
3.1. GIST-associated malignancies
The 86 GIST patients included 50 men and 36 women with an
age range of 35e91 (mean age was 64.8 years and 67.4 years for
men and women, respectively). There was a slight male predomi-
nance in our series (M:F ¼ 1.4:1). Thirty-seven patients (43%) were
identiﬁedwith non-GISTmalignancy. Five of the 37 patients (13.5%)
suffered from more than one other malignancy in addition to GIST.
Among the 37 patients were 27 men (73%) and 10 women (27%)
with a mean age of 70 years (range 56e86). Male predominance
was even higher in the group with other malignancies (2.7:1). The
mean agewas 68 years (range: 60e80) and 75 years (range: 56e86)
for men andwomen, respectively. Thus, mean agewas higher in the
group with associated malignancies than those without (70 yrs vs.
65.7 yrs). The most common localisation of GIST was the stomach
(24 cases, 65%) (Fig. 1a), followed by the small intestine (11 cases,
30.6%) (Fig. 1b), oesophagus (1 case, 2.7%) and rectum (1 case, 2.7%).
Small intestinal GISTs were located in the duodenum (n ¼ 3),
jejunum (n ¼ 2) and ileum (n ¼ 6) (Table 1). Of the 42 identiﬁed
associated non-GIST neoplasms, the majority (69%) was located in
the gastrointestinal and hepato-pancreato-biliary tract (7 gastric
carcinomas, 5 rectal adenocarcinomas, 4 esophageal carcinomas, 4
pancreatic adenocarcinomas, 3 colon carcinomas, 2 carcinomas ofthe papilla of Vater, 1 hepatocellular carcinoma). The remaining
cases were represented by pharyngeal carcinomas (n ¼ 2), plasma
cell myeloma (n ¼ 2), malignant melanoma (n ¼ 2), squamous cell
skin carcinoma (n¼ 1), prostatic adenocarcinoma (n¼ 3), urothelial
carcinoma (n ¼ 1), renal cell carcinoma (n ¼ 1), neuroendocrine
tumour in colon (n¼ 1), thyroid carcinoma (n¼ 1) and anaplastic T-
non-Hodgkin lymphoma (n ¼ 2) (Table 2). In twenty-nine patients
(78%), detection of the GIST and the second tumour was simulta-
neous. In ﬁve patients of them there were two non-GIST malig-
nancies either preceding (n ¼ 4) or following (n ¼ 1) the diagnosis
of GIST. The mean time interval between previous additional ma-
lignancy and GIST was 97 months (range: 40e156 months). In six
patients (16%) GIST was found during follow-up for a known other
malignancy and in two patients (5.5%), the second malignancy was
detected after the diagnosis of GIST. In one patient, two separate
GIST were found in the same organ (stomach). The chronology of
GIST diagnosis is detailed in Table 2. GIST were almost always an
incidental ﬁnding either during the diagnostic procedures for other
tumours (5 cases, 14%) or during surgery (24 cases, 65%). Only 8
GIST (21%) presented with clinical symptoms (abdominal pain,
bleeding); four of them were not synchronous with other
malignancies.
Table 1
Localisation and risk classiﬁcation of GIST.
GIST lokalisation GIST; n (%) Risk classiﬁcation; n (%) Localisation of other malignancy; n (%)
No Very low Low Intermediate High GI Skin cancer Uro. Thyroid Hamato.
Stomach 24 (65) 17 (65) 4 (100) 1 (100) 2 (33) 0 19 (65.5) 1 (33) 2 (40) 0 (0) 2 (50)
Small intestine 11 (30.6) 7 (27) 0 (0) 0 (0) 4 (67) 0 8 (27.5) 2 (67) 3 (60) 1 (100) 2 (50)
Duodenum 3/11 (27) 1/6 (14) 0 (0) 0 (0) 2/4 (50) 0 (0) 2/8 1 1 0 0
Jejunum 2/11 (18) 2/6 (29) 0 (0) 0 (0) 0 (0) 0 (0) 3/8 0 0 0 0
Ileum 6/11 (55) 4/6 (57) 0 (0) 0 (0) 2/4 (50) 0 (0) 3/8 1 2 1 2
Oesophagus 1 (2.7) 1 (4) 0 (0) 0 (0) 0 (0) 0 (0) 1 (3.5) 0 (0) 0 (0) 0 (0) 0 (0)
Rectum 1 (2.7) 1 (4) 0 (0) 0 (0) 0 (0) 0 (0) 1 (3.5) 0 (0) 0 (0) 0 (0) 0 (0)
Total 37 (100) 26 (100) 4 (100) 1 (100) 6 (100) 0 (0) 29 (100) 3 (100) 5 (100) 1 (100) 4 (100)
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The majority of patients (35/37, 94.5%) underwent open surgery,
and two patients (5.5%) underwent laparoscopic or endoscopic
excision. Thirty-six tumours (97.5%) were completely resected (R0)
and one was not resectable due to initial inﬁltration into the
mesentery, which was coexistent with a ductal adenocarcinoma of
pancreas, diagnosed nine months later. Three patients received
imatinib mesylate (400 mg/d) treatment. One patient with anTable 2
Patient Characteristics, features of GIST and associated malignancies.
Patients GIST
No. Sex Age Lokalisation Size (mm) Risk GIST diagnosis
1 M 65 Stomach 40 Low 3 months later
2 M 63 Stomach 10 Very low Simultaneous
3 F 75 Ileum (meckel) 15 no Simultaneous
7 years later
4 M 59 Stomach 2 No 11 years later
5 M 62 Stomach 4 No Simultaneous
6 M 62 Duodenum 18 No Simultaneous
13 years later
7 M 60 Oesophagus 12 e Simultaneous
8 F 56 Ileum 12 No Simultaneous
9 F 67 Duodenum 80 Intermediate 9 months earli
10 M 64 Jejunum 20 No Simultaneous
11 M 71 Stomach 30 Very low Simultaneous
12
13
M
M
69
73
Rectum
Stomach
4
8
No
No
Simultaneous
12 months late
14 M 65 Stomach 100 Intermediate Simultaneous
15 M 65 Jejunum 18 No Simultaneous
40 months late
16 F 81 Ileum 15 No Simultaneous
42 months ear
17 M 74 Stomach 15 No Simultaneous
18 F 76 Stomach 12 No Simultaneous
19 M 77 Ileum 53 Intermediate 48 months late
20 M 68 Stomach 90 Intermediate Simultaneous
21 M 60 Ileum 7 No Simultaneous
22 M 77 Stomach 8 No Simultaneous
9 years later
23 M 72 Ileum 55 Intermediate 14 years later
24 M 67 Stomach 2 No 72 months late
25 M 80 Stomach 8 No Simultaneous
26 M 70 Stomach 25 Very low Simultaneous
27 F 71 Stomach 13 No Simultaneous
28 F 86 Stomach 3 No Simultaneous
29 F 74 Stomach 3 No Simultaneous
30 M 69 Stomach 4 No Simultaneous
31 M 66 Stomach 10 No Simultaneous
32 M 64 Stomach 5 No Simultaneous
33 F 80 Stomach 1 No Simultaneous
34 M 72 Stomach 25 Very low Simultaneous
35 M 69 Stomach 5 No Simultaneous
36 M 70 Duodenum 65 Intermediate 24 months ear
37 F 82 Stomach 4 No Simultaneousintermediate risk GIST in duodenum received neoadjuvant imatinib
therapy. The second one with GIST in stomach received neo-
adjuvant therapy for 5 months because of preoperative suspicion of
hepatic metastasis on MRI. He underwent an excision of the gastric
GIST ﬁve months later. The liver mass was resected and found to be
a hepatocellular carcinoma. This patient received adjuvant imatinib
mesylate therapy for three years. This patient remained disease free
currently (55 months after surgery). The last patient with an in-
termediate risk duodenal GIST received neoadjuvant therapyGIST associated malignancy
Tumour type Localisation UICC-stage
Malign melanoma Temple IA
Adenocarcinoma oesophagus IIIA
Adenocarcinoma
follicular carcinoma
Colon ascendens
thyroid gland
IIA
IIIA
Plasmacytoma Diffuse IIIB
adenocarcinoma Papilla IB
ductal adenocarcinoma
renal cell carcinoma
Pancreas
Kidney
IVB
Unknown
Squamous cell carcinoma Oesophagus IIIA
Metastases of malignant melanoma Unknown IV
er Ductal adenocarcinoma Pancreas Unknown
Ductal adenocarcinoma Pancreas IV
Adenocarcinoma Prostate Unknown
r
Adenocarcinoma
T-non-Hodgkin lymphom
Rectum
Bone marrow
IIA
Unknown
Adenocarcinoma Papilla IB
r
Ductal ADENOCARCINOMA
Squamous cell carcinoma
Papilla
Pharynx
IVA
III
lier
Neuroendocrine tumour
Anaplastic T-non-Hodgkin lymphom
Colon
Bone marrow
IIIB
Unknown
Adenocarcinoma Rectum IIIB
Adenocarcinoma Rectum IIA
r Plasmacytoma Diffuse IIB
Hepatocellular carcinoma Liver I
Adenocarcinoma with liver metastases Colon (sigmoid) IV
Adenocarcinoma
Adenocarcinoma
Rectum
Prostate
IA
Unknown
Transitional cell carcinoma Urothelium Unknown
r Squamous cell carcinoma Skin Unknown
Adenocarcinoma Stomach IIIA
Squamous cell carcinoma Oropharynx III
Adenocarcinoma Stomach IA
Adenocarcinoma Stomach IIIA
Signet-ring cell carcinoma Stomach IA
Adenocarcinoma Oesophagus IA
Adenocarcinoma Stomach IA
Adenocarcinoma Oesophagus IV
Adenocarcinoma Colon asc IIIB
Adenocarcinoma Rectum IIA
Adenocarcinoma Stomach IB
lier Adenocarcinoma Prostate II
Signet-ring cell carcinoma Stomach IB
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this period (24 months after the diagnosis of GIST) a second ma-
lignancy (prostate adenocarcinoma) was diagnosed.
3.3. Histopathological features and risk classiﬁcation of GISTs
associated with other malignancies
Thirty-ﬁve cases (95%) were of spindle-cell,1 was epithelioid and
1 was of mixed histological type. According to the Fletcher et al.’s
classiﬁcation [7], GIST with a very low risk of aggressive behaviour
were most common (26 cases, 70.3%), while GIST with a low risk
were represented by 4 cases (37.8%). Only 6 cases had intermediate
risk (16.2%). Only 1 high risk GIST was observed. According to the
Miettinen and Lasota’s classiﬁcation [8], most GISTs could be clas-
siﬁed as none risk tumours (25 cases, 67.5%) or as very low (4 cases,
10.8%), low (1 case, 2.7%) or intermediate (6 cases, 16.2%). No high
risk GIST was observed according to this risk system. One case could
not be classiﬁed because of preoperative therapy.
3.4. GIST follow-up and disease outcome for the very low/low risk
groups
Duration of follow-up varied between 3 and 160 months with a
mean follow-up of 66 months. No recurrences or metastases from
GIST were detected on last follow-up. Currently, most patients
(n¼ 20, 64.5%)were alivewhile 6 patients (19.5%) died of recurrence
or distant metastasis of the associated other malignancy, 2 patients
(6.5%) died postoperatively in the setting of therapeutic procedures
for the other malignancy and the remaining patients (n ¼ 3, 9.5%)
died of other non-tumour-associated cause. No patient died of GIST.
3.5. Disease outcome of the intermediate risk group
Duration of follow-up varied between 10 and 72 months with a
mean follow-up of 40 months. Currently, most patients (n ¼ 4,
66.7%) were alive. One patient with a gastric GIST received neo-
adjuvant imatinib mesylate therapy because of suspicion of liver
metastasis on MRI. Five months later, he underwent excision of
both lesions. However, the liver tumour was diagnosed as hepa-
tocellular carcinoma. He received adjuvant imatinib therapy for 3
years. He remained disease-free at last follow 70 months later.
Another patient was diagnosed with a duodenal GIST through a CT-
guided biopsy followed by neoadjuvant imatinib therapy and then
Whipple operation. Postoperatively he received imatinib mesylate
for 2 years and 24 months after the diagnosis of GIST a second
malignancy (prostate adenocarcinoma) was diagnosed. Another
patient with unresectable duodenal GIST received neoadjuvant
therapy and was diagnosed with ductal adenocarcinoma of
pancreas 9 months later. This patient died of pancreas cancer. The
only patient with intermediate risk GIST with malignant behaviour
was diagnosed with ileal GIST, which was excised. Two years later
GIST metastasis was diagnosed in the peritoneum, jejunal wall and
abdominal wall. He underwent emergency operation due to
massive gastrointestinal bleeding and he died of postoperative
complications with multi-organ-failure. This patient had a history
of multiple myeloma.
4. Discussion
GIST usually develop as a sporadic disease. Rare diseases/syn-
dromes have been indentiﬁed, in which coexistence of GIST and
other neoplasms may share a common etiopathogenesis [16e20].
Recent studies have shown a higher concurrence of GIST with other
malignant tumours of different histogenesis than previously
believed [21e28]. Undoubtedly, the frequency of associated otherneoplasms in the different studies is affected by the type of study
centre which determines the nature of the material used for
detailed examinations. A problem is that in some studies the pro-
portion of tumours coexisting with GIST includes exclusively ma-
lignant tumours, while in other studies all neoplasms, benign or
malignant, are considered. Additionally in some centres GIST were
sometimes not systematically recorded in cancer statistics since the
terminology and the diagnostic criteria of GIST have been estab-
lished only recently and as a result, epidemiological data may be
incorrect or incomplete.
However, there is currently a continuously increasing knowl-
edge about synchronous presentation of GIST and other gastroin-
testinal tumours. Kalmar et al. found that the frequency of
malignant neoplasms among patients with a GIST (21.7%) is
signiﬁcantly higher than that in the general population (4%,
p < 0.001) [28]. Many types of GIST-associated malignancies are
reported in the literature [28e60]. In our study GIST associated
with other malignancies occurred in 37 of our 86 (43%) patients.
Thus, our current study represents the highest coincidence ever
reported, since the reported frequencies of second malignancies in
GIST patients have ranged from 2.95% [21] to 33% [61] in different
series (mean frequency in all previous studies: 10% [13]).
Carcinomas of the gastrointestinal tract are the most frequent
neoplasms associated with concomitant GIST, and of them gastric
and colorectal adenocarcinomas were the leading types in
concordance with the literature [13]. In our study, almost all pa-
tients with synchronous coexistence of GIST with other malig-
nancies were asymptomatic, and GIST in these patients were
discovered incidentally during diagnostic or therapeutic pro-
cedures for the other tumours. This could be explained by the fact
that GIST-related symptoms might have been overlooked because
of the more serious progressing symptoms of the other malignancy
such as severe dysphagia, weight loss, abdominal pain and
anaemia. Another hypothesis is that GIST may have developed later
than the other malignancy or that the development of symptoms of
stromal tumours may have been masked by symptoms of the
associated neoplasm.
Of the 8 symptomatic GIST patients in our study, 6 were not
associated with a synchronous malignancy. Generally the preop-
erative detection rate of incidental tumours is very low. Indeed, in
most of our cases of synchronous gastrointestinal malignancies and
GIST, histological diagnosis of the GIST was not achieved preoper-
atively but the GIST were detected only during laparotomy or on
examination of the resection specimen. This fact underlines the
importance of a thorough intra-operative inspection of the
abdominal cavity to detect smaller lesions. While recognition and
histological veriﬁcation of small GIST nodules and their separation
from metastasis from a synchronous or previously treated malig-
nancy is important for appropriate staging, missing incidental GIST
during diagnostic and therapy for other tumours may be the source
of future problem for long term survivors of the treatedmalignancy,
as these smaller lesions may further progress to a symptomatic and
potentially malignant tumour.
Of note, most synchronous GIST were of very low/low risk and
most of non-synchronous cases were larger but mitotically less
active neoplasms that ﬁtted the intermediate risk group (Fig. 2).
This is why imatinib mesylate was not administrated in patients in
our study except for 3 patients. In our study only 1 patient, with
GIST of intermediate risk localized in ileum developed metastases
(peritoneum and abdominal wall), but the GIST was not synchro-
nous to the second malignancy. Notably, the other coexistent ma-
lignancies had a greater adverse impact on prognosis than did GIST,
since no one of our patients died of GIST, and there was no statis-
tically signiﬁcant correlation between the GIST’s progress and the
UICC classiﬁcation of the other malignancy (data not shown).
Fig. 2. Risk classiﬁcation of synchronous and asynchronous GIST with other
malignancies.
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question of whether such an occurrence was coincidental or
whether both neoplasms were casually related. However to date,
little is known about the etiology of this phenomenon, but various
hypotheses have been proposed. The development of these tu-
mours may involve unknown carcinogenic agents, which inﬂuence
neighbouring tissues, resulting in a simultaneous proliferation of
different cell lines i.e. epithelial and stromal cells. Experimental
evidence for this hypothesis has been provided [62e64]. Oral
administration of N-methyl-N-nitro-N-nitrosoguanidine (MNNG)
in rats induced the development of gastric adenocarcinomas,
almost exclusively localized in the pyloric region of the stomach or
in the duodenum [62]. If combined with other agents that alter the
gastric mucosal barrier (such as nonsteroidal anti-inﬂammatory
drugs, stress, sodium taurocholate) leiomyosarcoma can be
induced in association with the epithelial tumour [63]. Another
possible carcinogenic agent is 9,10-dimethyl-1,2-benzanthracene
(DMBA). There is some evidence that this compound by itself in-
duces gastric adenocarcinoma of rats after nine administrations by
injection, whereas administration of DMBA combined with cello-
phane plate can induce the development of gastric sarcomas.
However, there is no evidence to show that these compounds play
important roles in human gastric carcinogenesis [64].
Theoretically, genetic mutations or combined genetic deregu-
lation could also play an important role in the pathogenesis of
gastric synchronous tumours. However, no available evidence
supports a common genetic alteration of adenocarcinoma and GIST
at present.
Au et al. proposed that the coexistence of a GIST with renal
papillary carcinoma may result from mutation of protooncogenes
coding tyrosine kinases, c-KIT and c-MET, respectively [65]. This
phenomenon may be analogous to the c-RET protooncogene mu-
tation observed in multiple endocrine neoplasia (MEN 2A).
Frequent c-KIT and c-MET coexpression in solid tumours may
indirectly indicate common regulatory mechanisms [65]. In this
regard, it is noteworthy that presence of a mutation or deregulated
c-KIT expression apart from GIST is also observed in a wide variety
of human malignancies besides GIST, including chronic myeloid
leukaemia (CML), germ cell tumours, small cell lung carcinoma
(SCLC), neuroblastoma, melanoma, ovarian carcinoma, breast car-
cinoma, exocrine and endocrine pancreatic tumours and colorectal
carcinoma [66e71]. Miettinen et al. have reported a non-random
and statistically association of GIST and acute myeloid leukaemia
[72]. Regarding the Helicobacter pylori infection, although it has
been implicated as a carcinogen of the stomach by the World
Health Organization in 1994 [73] and strongly associated with
gastric MALT lymphoma [74,75] at present, there is no evidence
that links GIST development to H. pylori infection. Apart from the
above mentioned theories, simple coincidence could also be thecase, especially in centres having high incidence rates of gastric
surgery [29.32]. The mean age of patients with a GIST and a second
malignancy is higher than the age of patients with only a GIST in
our cohort (70 vs. 65.7 years, respectively). This ﬁnding is in
accordance with the well known increase in carcinoma incidence
with increasing age and is consistencewith the notion of amere co-
incidence.5. Conclusion
In conclusion, we have documented the occurrence of other-
type malignancies in 43% of patients with GIST at our institute,
the highest incidence reported to date. The concurrence of other
malignancies and GIST raises questions about a potential common
origin and carcinogenetic mechanisms in these distinct tumour
types thus meriting future studies. It seems that the prognosis in
this subset of GIST patients is mainly determined by the other
malignancy and not by GIST. Therefore treatment algorithms
should focus on the prognostically relevant malignancy. Finally, a
thorough intra-operative inspection of the abdominal cavity sup-
plemented by awareness of GIST and their morphological and
biological characteristics is mandatory for recognition of coinci-
dental GIST and their correct interpretation to avoid inappropriate
under- or overtreatment of the patients.Ethical approval
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